High Proportion of School Aged Children Susceptible to Mumps Virus Infections in the City of Mwanza, Tanzania: Should It be Included in the National Immunization Programme?

Main Article Content

Ruth B. Rakiru
Delfina R. Msanga
Rose Laisser
Doreen Kamori
Mtebe Majigo
Stephen E. Mshana
Mariam M. Mirambo
Dina Mahamba

Abstract

Aim: This study for the first time in Mwanza, Tanzania aimed at determining seropositivity of mumps virus in school aged children who are targeted for vaccination.

Study Design: Cross-sectional study.

Place and Duration of the Study: This study was conducted in the city of Mwanza from July to September 2018.

Despite being common with reported associated complications in many resource limited countries, there is scarcity of information on its epidemiology in Tanzania.

Methodology: We enrolled 440 school children aged 6-12 years. Data was collected using a pre-tested structured data collection tool. Blood samples were collected, and sera were used for detection of mumps virus antibodies by indirect enzyme linked immunosorbent assay (ELISA). Data was analyzed using STATA version 13, 2013.

Results: The median age of enrolled children was 9(IQR: 8-11) years. The seropositivity of mumps IgG antibodies was found to be 94(21.4%, 95% CI: 17.5-25.1) while that of IgM was 1 (0.23%, 95% CI: 0.02-0.6). By multivariable logistic regression analysis, residing in rural areas (OR: 2.28, 95% 1.42-3.36, P=0.001) and age >10 years (OR: 1.67, 95% CI: 1.03-2.7, P=0.036) independently predicted mumps IgG seropositivity.

Conclusion: A significant proportion of young children in urban areas of the city of Mwanza are susceptible to mumps virus infection indicating the need to generate more data across the country so as to institute appropriate control measures including measles, mumps and rubella (MMR) vaccination programme.

Keywords:
Mumps virus, seropositivity, Mwanza, vaccination, Tanzania.

Article Details

How to Cite
Rakiru, R. B., Msanga, D. R., Laisser, R., Kamori, D., Majigo, M., Mshana, S. E., Mirambo, M. M., & Mahamba, D. (2020). High Proportion of School Aged Children Susceptible to Mumps Virus Infections in the City of Mwanza, Tanzania: Should It be Included in the National Immunization Programme?. International Journal of TROPICAL DISEASE & Health, 41(15), 46-55. https://doi.org/10.9734/ijtdh/2020/v41i1530357
Section
Original Research Article

References

Al-kadassy AM, AL-Robasi A-BA, Shamah HA, Alkadasi MN, Kamal MKA, Zaid AA. Serological analysis of mumps virus antibodies among school children in Hodeidah city, Yemen. Int J Curr Microbiol App Sci. 2014;3(12):52-61.

Richardson M, Elliman D, Maguire H, Simpson J, Nicoll A. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J. 2001;20(4):380-91.

Planning F, Procurement V. Immunization News. SAGE. 2010;13:15.

Orlíková H, Malý M, Lexová P, Šebestová H, Limberková R, Jurzykowská L, et al. Protective effect of vaccination against mumps complications, Czech Republic, 2007–2012. BMC Public Health. 2016; 16(1):293.

Enders M, Rist B, Enders G. Frequency of spontaneous abortion and premature birth after acute mumps infection in pregnancy. Gynakologisch-geburtshilfliche Rundschau. 2005;45(1):39-43.

Malaiyan J, Nellapillai SR, Ramanan PV, Gokul A. Serum Th1/Th2 Cytokine Levels During Acute Mumps Infection: Prediction to Infertility Patients with History of Mumps Infection.

Hazama K, Shiihara T, Tsukagoshi H, Hasegawa S, Dowa Y, Watanabe M. A case of mumps-related acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev. 2017; 39(9):808-10.

Khalifa AFM, A.F.M. Khalifa, and O. Elmustafa. Aetiological factors and clinical presentation of hearing loss among sudanese children attending Khartoum teaching hospital. Eur J Pharm Med Res. 2017;4:139-42.

White DO, Fenner F. Med Virol: Gulf Professional Publishing; 1994.

White SJ, Boldt KL, Holditch SJ, Poland GA, Jacobson RM. Measles, mumps, and rubella. Clin Obstet Gynaecol. 2012; 55(2):550.

Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review/AM Galazka, SE Robertson, and A. Kraigher; 1999.

Watkins J. Mumps: An overview of the diagnosis and complications. BJSN. 2011; 6(2):73-6.

WHO vaccine-preventable diseases: Monitoring system: 2009 Global Summary; 2009.

Briss PA, Fehrs LJ, Parker RA, Wright PF, Sannella EC, Hutcheson R, et al. Sustained transmission of mumps in a highly vaccinated population: Assessment of primary vaccine failure and waning vaccine-induced immunity. ‎J. Infect. Dis. 1994;169(1):77-82.

Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull. World Health Organ. 1999; 77(1):3.

CDC. Recommendation of the Public Health Service Advisory Committee on Immunization Practices: Mumps vaccine; 1977.

Marin M, Marlow M, Moore KL, Patel M. Recommendation of the advisory committee on immunization practices for use of a third dose of mumps virus–containing vaccine in persons at increased risk for mumps during an outbreak. Morb. Mortal. Wkly. Rep. 2018;67(1):33.

Gurgoze M, Yilmaz E, Godekmerdan A, Akça Z, Dogan Y, Akarsu S, et al. Seroprevalence of mumps, varicella and rubella antibodies in children 1-16 years of age in eastern Turkey. Turk. J. Pediatr. Dis. 2006;48(3):185.

Doshi RH, Alfonso VH, Hoff NA, Mukadi P, Gerber S, Bwaka A, et al. Evidence of Mumps Infection Among Children in the Democratic Republic of Congo. Pediatr. Infect. Dis. J. 2017;36(5):462-6.

McIntyre J, Keen G. Laboratory surveillance of viral meningitis by examination of cerebrospinal fluid in Cape Town, 1981–9. Epidemiol. Infect. 1993; 111(2):357-71.

Minja B. Aetiology of deafness among children at the Buguruni School for the Deaf in Dar es Salaam, Tanzania. Int. J. Pediatr. Otorhinolaryngol. 1998;42(3):225-31.

Yamane T. Taro Yamane’s formula; 1973.

Lebo EJ, Kruszon-Moran DM, Marin M, Bellini WJ, Schmid S, Bialek SR, et al., editors. Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009–2010. Open Forum Infect. Dis. Oxford University Press; 2015:

Kanbur NO, Derman O, Kutluk T. Age-specific mumps seroprevalence of an unvaccinated population of adolescents in Ankara, Turkey. J. Infect. Dis. 2003; 56(5/6):213-5.

Santacruz-Sanmartín E, Hincapié-Palacio D, Ospina MC, Perez-Toro O, Bernal-Restrepo LM, Buitrago-Giraldo S, et al. Seroprevalence of mumps in an epidemic period in Medellín, Colombia. Vaccine. 2015;33(42):5606-12.

Ternavasio-de la Vega H-G, Boronat M, Ojeda A, García-Delgado Y, Angel-Moreno A, Carranza-Rodríguez C, et al. Mumps orchitis in the post-vaccine era (1967-2009): a single-center series of 67 patients and review of clinical outcome and trends. Medicine. 2010;89(2):96-116.

Beard C, Benson JR, Kelalis P, Elveback L, Kurland L, editors. The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974. Mayo Clinic Proceedings; 1977.

FOY HM, COONEY MK, HALL CE, Bor E, MALETZKY AJ. Isolation of mumps virus from children with acute lower respiratory tract disease. Am. J. Epidemiol. 1971; 94(5):467-72.

Avijgan M, Habibian R, Kheiri S. Seroprevalence of mumps before inclusion of mumps vaccination in the Iranian Expanded Programme on Immunization. Am. J. Epidemiol. 2009;15(2):295-301.

Dos Santos BA, Stralioto SM, Siqueira MM, Ranieri TS, Bercini M, Schermann MT, et al. Prevalence of antibodies against measles, mumps, and rubella before and after vaccination of school-age children with three different triple combined viral vaccines, Rio Grande do Sul, Brazil, 1996. Pan Am. J. Public Health. 2006; 20(5):299.

Bockelman C, Frawley TC, Long B, Koyfman A. Mumps: An emergency medicine-focused update. Int. J. Emerg. Med. 2018;54(2):207-14.

Gürgöze MK, Yilmaz E, Gödekmerdan A, Akça Z. Seroprevalence of mumps, varicella and rubella antibodies in children 1-16 years of age in eastern Turkey. Turk. J. Pediatr. Dis. 2006;48(3):185.

Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. Br. Med. J. 2005;330(7500):1132-5.